Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit |  |
|
Posted by Mary Canady June 7th, 2009 .
| |
| No Comments |
The dust has settled in the boardroom battle for control over Amylin Pharmaceuticals, and now it’s time to get back to fundamentals. The San Diego-based biotech company hopes to grab the...
[[Click headline to continue reading.]]
[[Click headline to continue reading.]]
See other entries categorized in News, Syndication, Xconomy.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
